Modulation of Molecular Biomarker Expression in Response to Chemotherapy in Invasive Ductal Carcinoma

Table 5

Biomarker expression and coexpression regarding its association with HER2, ER/PR.

(a) Marker expression in phase I (before surgery)

Biomarkers expression	Luminal; HER2^−/+, ER^+/PR^+		Basal-like; HER2^−, ER^−/PR^−		value
	N	%	N	%
CK19	14	50	14	50	0.17
Myc	10	66.7	5	33.3	0.14
Ki-67	15	60	10	40	0.10
CEA	10	66.7	5	33.3	0.14

value ≤ 0.05 was considered statistically significant.

(b) Marker coexpression in phases I (before surgery) and II (after treatment)

Biomarker  coexpression	Phase I				value	Phase II				value
	Luminal like; HER2^−/+, ER^+/PR^+		Basal-like; HER2^−, ER^−/PR^−			Luminal like HER2^−/+, ER^+/PR^+		Basal like; HER2^−, ER^−/PR^−
	N	%	N	%		N	%	N	%
CK19, Ki-67, Myc, CEA	8	61.5	5	38.5	0.4	0	0	0	0	—
CK19, Ki-67, Myc	8	61.5	5	38.5	0.4	0	0	0	0	—
CK19, Ki-67	12	54.5	10	45.5	0.8	10	100	0	0	≤0.001

value ≤ 0.05: correlation was considered statistically significant.